Skip to content

Inspection Record

Kedrion BioPharma, Inc. — FDA 483 Findings

US FDAInspected 2019-12-06Published 2026-10-26 4 findingsData integrityProcess validationDeviation, CAPA, and investigationContamination control

View the regulator's official source The source document is always the basis for judgement.

Findings

1Data integrity

Appropriate controls for data integrity were not exercised over computers used during PPQ lots.

2Process validation

Written production and process control procedures were not followed in the execution ofthe various production and process control functions during the PPQ runs for RhoGAM S(H)4YW Incidences include, but are not limited to, the following: a.

3Deviation, CAPA, and investigation

Deviation investigations are not well documented.

4Contamination control

Procedures designed to control microbiological contamination are not established.

A record as of the US FDA document published on 2026-10-26. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Kedrion BioPharma, Inc. company profile — full historyAll US FDA findings US FDA documents, 2026 Go to Findings search
Linked from (backlinks)
Briefs that featured this document
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.